Family-owned CDMOs in Europe: 101 compared (2026)
101 of the 255 contract development and manufacturing organisations in A4BEE’s European census are family-owned. The largest, with revenue over €1bn, are ACS Dobfar, Almac Group, Biovet (Huvepharma), BSP Pharmaceuticals, ESTEVE (Química / CDMO), Fareva and 4 more. 23 sit between €250m and €1bn and 68 are smaller or niche.
By ownership: 101 family-owned. They are spread across 26 countries, led by Germany (14), Spain (14), Italy (12), Portugal (6) and Greece (5). 51 of the 101 rows rest on audited reports or official company disclosures; the rest come from secondary sources or estimates.
101 companies
Family-owned CDMOs in Europe
| Company | Country | Ownership | Size | Revenue (as reported) | Modalities | Data |
|---|---|---|---|---|---|---|
| ACS DobfarItalian anti-infectives specialist (1973). Vertically integrated: cephalosporin/carbapenem/penicillin APIs AND finished dosage on a CDMO basis. | Tribiano, Italy | Family-owned | Tier 1 | not disclosed | Small-molecule API, Sterile fill-finish, Oral solid dose | high |
| Almac Group£400 m+ capex program; broad clinical + diagnostics services alongside API. | Craigavon, United Kingdom | Family-ownedMcClay charitable trust | Tier 1 | £1.027 bn FY2024 | Small-molecule API, Peptide, Antibody-drug conjugate (ADC) | high |
| Biovet (Huvepharma)Huge fermentation platform — mainly own animal-health APIs but offers custom synthesis/fermentation and human-health APIs. CDMO relevance is microbial API. | Peshtera, Bulgaria | Family-ownedHuvepharma / Domuschiev family | Tier 1 | not disclosed | Microbial and protein, Small-molecule API | low |
| BSP PharmaceuticalsLeading oncology CDMO: ADC conjugation + highly-potent aseptic fill-finish from clinical to commercial. Serves ~80 countries. | Latina, Italy | Family-ownedBraca family | Tier 1 | €532.7 m (2024) | Sterile fill-finish, Antibody-drug conjugate (ADC), Monoclonal antibody, Oral solid dose | high |
| ESTEVE (Química / CDMO)Self-described 'Champion Small-Molecule CDMO'; APIs, HPAPIs and advanced intermediates for third parties. | Barcelona, Spain | Family-ownedEsteve family | Tier 1 | not disclosed | Small-molecule API | high |
| Fareva | Luxembourg, Luxembourg | Family-owned | Tier 1 | ~€2.2 bn | Sterile fill-finish, Oral solid dose, Small-molecule API, Monoclonal antibody | medium |
| HovioneFully integrated specialist CDMO: API, particle engineering/spray drying, drug product. FDA-inspected across 3 continents. | Loures, Portugal | Family-ownedVillax family | Tier 1 | not disclosed | Small-molecule API, Oral solid dose | high |
| Insud Pharma (Chemo)Group-level entity. Chemo industrial division provides CMO/CDMO across most dosage forms incl. injectables. Parent of Liconsa and León Farma. | Madrid, Spain | Family-ownedGrupo Insud | Tier 1 | not disclosed | Small-molecule API, Oral solid dose, Sterile fill-finish, Biologics and biosimilars, Monoclonal antibody | high |
| OlonOne of Europe's largest API CDMOs; absorbed Euticals. Chemical synthesis + microbial fermentation, HPAPI, ADC bioconjugation. | Rodano, Italy | Family-owned | Tier 1 | ~€546 m (2024, group) | Small-molecule API, Microbial and protein, Peptide, Antibody-drug conjugate (ADC), Biologics and biosimilars | high |
| Vetter PharmaSterile fill-finish specialist (vials, syringes, cartridges). | Ravensburg, Germany | Family-owned | Tier 1 | n/d (large) | Sterile fill-finish | medium |
| Adamed Pharma | Pieńków, Poland | Family-owned | Tier 2 | >PLN 1.6 bn (2023) | Small-molecule API, Oral solid dose | medium |
| Aenova GroupMulti-site OSD/softgel/sterile group; acute data-silo profile across 14 sites. | Starnberg, Germany | Family-ownedKühne Holding | Tier 2 | n/d | Oral solid dose, Sterile fill-finish | medium |
| BioSpringPrivately held German nucleic-acid CDMO (oligonucleotides — ASO, siRNA, guide RNA — plus mRNA). Fills a modality gap the roster otherwise lacks. | Frankfurt am Main, Germany | Family-owned | Tier 2 | not disclosed | mRNA and LNP, Small-molecule API | medium |
| BluepharmaIntegrated CRDMO. OSD capacity ~2bn units/year plus complex injectables and LNP work. FDA-inspected 5×. | Coimbra, Portugal | Family-owned | Tier 2 | not disclosed | Oral solid dose, Sterile fill-finish | high |
| Delpharm | Boulogne, France | Family-owned | Tier 2 | ~€650 m | Oral solid dose, Sterile fill-finish, Biologics and biosimilars | medium |
| DEMOPrimarily own-product (largest injectables supplier to Greek hospitals) but lists contract manufacturing. Own-API from 2019. | Krioneri, Greece | Family-owned | Tier 2 | not disclosed | Sterile fill-finish, Small-molecule API | medium |
| Dipharma FrancisGlobal CDMO + generic API manufacturer (>40 APIs) plus exclusive/custom synthesis. FDA-inspected. | Baranzate, Italy | Family-owned | Tier 2 | not disclosed | Small-molecule API | medium |
| Farmhispania GroupIndependent private API CDMO; leading European CDMO in HPAPI (cytotoxics) plus fermentation and large-scale lyophilisation. | Montmeló, Spain | Family-owned | Tier 2 | not disclosed | Small-molecule API, Microbial and protein | high |
| FlammaFamily-owned small-molecule API CDMO since 1950; leader in amino acids and peptide building blocks. FDA-inspected. | Chignolo d'Isola, Italy | Family-ownedNegrisoli family | Tier 2 | not disclosed | Small-molecule API, Peptide | high |
| GrindeksMajor Baltic pharma that formally launched CDMO services (2025): API dev/manufacturing incl. HPAPIs, plus solid/liquid/semi-solid FDFs. Sterile injectables via Kalceks. | Riga, Latvia | Family-ownedKirovs Lipmans (majority) | Tier 2 | not disclosed | Small-molecule API, Oral solid dose, Sterile fill-finish | high |
| ICE (Industria Chimica Emiliana)World-leading integrated producer of bile-acid APIs (UDCA, TUDCA); custom-CDMO role narrower. Founded 1949. | Reggio Emilia, Italy | Family-owned | Tier 2 | not disclosed | Small-molecule API | medium |
| JGLLargest domestically-owned Croatian pharma and a genuine end-to-end sterile CMO — aseptic eye drops, nasal/bag-on-valve sprays. Expanding sterile capacity through 2026. | Rijeka, Croatia | Family-owned | Tier 2 | not disclosed | Sterile fill-finish | low |
| Kern PharmaDedicated 'Production to Third Parties' line. 3rd-largest Spanish generics producer by volume; chemical plant synthesises APIs. | Terrassa, Spain | Family-ownedGrupo Indukern | Tier 2 | not disclosed | Oral solid dose, Small-molecule API | high |
| Laboratorios NormonPrimarily own-product generics leader; offers CMO services via its International Division. CMO is a secondary line. | Tres Cantos, Spain | Family-owned | Tier 2 | not disclosed | Oral solid dose, Sterile fill-finish, Small-molecule API | medium |
| Laboratorios SalvatCDMO division specializes in sterile BFS liquids and single-dose ophthalmic/otic/nasal formulations. | Barcelona, Spain | Family-ownedPeris family | Tier 2 | not disclosed | Sterile fill-finish, Oral solid dose | high |
| MinakemAPI and HPAPI CDMO (custom synthesis). Brand of the privately-held Minafin Group. | Dunkerque, France | Family-ownedMinafin Group | Tier 2 | not disclosed | Small-molecule API | medium |
| RafarmEnd-to-end CDMO/CMO (50 yrs); third-party contract manufacturing of sterile ophthalmics and complex injectables (robotic sterile lines). | Paiania, Greece | Family-owned | Tier 2 | not disclosed | Sterile fill-finish | high |
| Rentschler BiopharmaComplex-protein pure-play; exited CGT in 2025 to refocus on biologics. | Laupheim, Germany | Family-owned | Tier 2 | ~US$296 m (2025) | Biologics and biosimilars, Monoclonal antibody, Microbial and protein | medium |
| Rottendorf Pharma~95-year-old foundation-owned CDMO focused on oral solid dosage forms. | Ennigerloh, Germany | Family-ownedRottendorf Foundation | Tier 2 | not disclosed | Oral solid dose | high |
| Sever Pharma SolutionsSpecialist CDMO for high-potent (OEB6)/cytotoxic/hormonal drug products and polymer-based delivery. Formerly QPharma. | Malmö, Sweden | Family-ownedNordic Group (Paulsen family) | Tier 2 | not disclosed | Oral solid dose | high |
| Special Product's Line (SPL)Italian CDMO specialized in non-sterile finished dose: oral solids, liquids and semi-solids for 60+ clients. EU-GMP. | Anagni, Italy | Family-owned | Tier 2 | not disclosed | Oral solid dose | high |
| Tecnimede (Atlantic Pharma)Primarily own-product/generics group that also offers contract manufacturing (solids/semi-solids/liquids). CMO secondary. | Sintra, Portugal | Family-ownedTecnimede Group | Tier 2 | not disclosed | Oral solid dose, Sterile fill-finish | medium |
| Vianex90+ yr firm; long-standing contract manufacturer (exclusive local/export production for MSD since 1983). Cephalosporins + solids/injectables. | Nea Erythraia, Greece | Family-ownedGiannakopoulos family | Tier 2 | not disclosed | Oral solid dose, Sterile fill-finish | high |
| 53BiologicsSpanish biologics CDMO (2017); recombinant proteins from DNA to protein — cell line dev, banking, GMP manufacturing. | Boecillo, Spain | Family-owned | Tier 3 | not disclosed | Biologics and biosimilars, Microbial and protein | medium |
| AdipharmPrivately-owned Bulgarian full-service CMO for solid dosage, semi-solids and oral liquids (dev, bulk, packaging incl. serialization). New €3.6M site (2022). | Sofia, Bulgaria | Family-owned | Tier 3 | not disclosed | Oral solid dose | high |
| Anfarm HellasEU-GMP manufacturer offering 3rd-party manufacturing / CDMO / tech transfer. Specializes in lyophilised products, liquid injectables, beta-lactams. | Kifissia, Greece | Family-owned | Tier 3 | not disclosed | Sterile fill-finish | high |
| APC / VLE TherapeuticsIrish-founded (UCD spinout). APC = process-dev/CMC; sister VLE runs the GMP 'factory of the future' — the group has genuine manufacturing. | Dublin, Ireland | Family-owned | Tier 3 | not disclosed | Small-molecule API, Biologics and biosimilars, Viral vector and vaccine, mRNA and LNP | high |
| Bilthoven BiologicalsVaccine CDMO (inactivated polio, viral-vector/Vero platforms; also mAbs). Owned by Serum Institute of India. | Bilthoven, Netherlands | Family-ownedSerum Institute of India | Tier 3 | not disclosed | Viral vector and vaccine, Biologics and biosimilars, Monoclonal antibody | high |
| BimedaIrish family-owned global animal-health company; contract/private-label veterinary manufacturing (drenches, nutritional liquids, ecto-parasiticides). | Dublin, Ireland | Family-owned | Tier 3 | not disclosed | Small-molecule API, Sterile fill-finish, Oral solid dose | medium |
| Bioindustria L.I.M.Own + third-party manufacturing. Sterile injectable/freeze-dried solutions and non-sterile tablets/capsules; also an API dept. | Novi Ligure, Italy | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose, Small-molecule API | high |
| BioinovaGMP contract manufacturer of ATMPs — stem-cell/MSC therapies for clinical trials. Spin-off of the Czech Academy of Sciences. | Prague, Czechia | Family-owned | Tier 3 | not disclosed | Cell and gene therapy | high |
| Cell-EasyCell-therapy CDMO (T/NK, MSCs, HSCs; autologous & allogeneic). Proprietary CellReady MSC platform. | Toulouse, France | Family-owned | Tier 3 | not disclosed | Cell and gene therapy | high |
| Celonic | Basel, Switzerland | Family-ownedJRS Group | Tier 3 | n/d | Monoclonal antibody, Biologics and biosimilars, Cell and gene therapy | medium |
| ChemConcGMP API / fine-chemical CDMO with high-containment HPAPI/cytotoxic capability; FDA-inspected. | Freiburg, Germany | Family-owned | Tier 3 | not disclosed | Small-molecule API | medium |
| Combino PharmGenerics developer that licenses out dossiers and offers third-party contract manufacturing, mainly via its Malta plant. | Sant Joan Despí, Spain | Family-ownedCorporación Medichem | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose, Small-molecule API | medium |
| CovexIndependent Spanish API maker since 1977; specialist in vinca alkaloids. CMO/CDMO for third-party API manufacturing. | Colmenar Viejo, Spain | Family-owned | Tier 3 | not disclosed | Small-molecule API | high |
| Croma-PharmaFamily-owned hyaluronic-acid specialist that contract-manufactures HA prefilled syringes for ortho/ophthalmology partners. | Leobendorf, Austria | Family-ownedPrinz family | Tier 3 | not disclosed | Sterile fill-finish | medium |
| CuridaFrom a 2015 buyout of Takeda's Elverum sterile-liquids plant. BFS + nasal-spray fill-finish CDMO, plus a small Bio-CDMO unit (mAbs for preclinical/diagnostic use). | Elverum, Norway | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Monoclonal antibody, Biologics and biosimilars | high |
| Custom Pharma ServicesFull-service oral-solid-dose CDMO (tablets/capsules/powders incl. HPAPI); process dev through commercial. Est. 1979. | Hove, United Kingdom | Family-owned | Tier 3 | not disclosed | Oral solid dose, Small-molecule API | high |
| DeretilGlobal leader in side chains for beta-lactam antibiotics; custom synthesis/enzymatic chiral tech. Founded 1961. | Cuevas del Almanzora, Spain | Family-owned | Tier 3 | not disclosed | Small-molecule API, Microbial and protein | high |
| ErregierreFamily company (1974) making small/medium-volume APIs (human + veterinary); contract manufacturing + DMF/CEP support. | San Paolo d'Argon, Italy | Family-ownedGargani family | Tier 3 | not disclosed | Small-molecule API | high |
| EscolitNewer (2021) Lithuanian CMO/CDMO for medicines and supplements — three full-cycle EU-GMP lines. Early stage; contract track record still thin. | Telšiai, Lithuania | Family-owned | Tier 3 | not disclosed | Oral solid dose | low |
| EVER PharmaSpecialty-injectables pharma that also runs a full CDMO for complex sterile injectables (cytotoxics, hormones, suspensions). | Unterach, Austria | Family-ownedB.F.H. Privatstiftung | Tier 3 | not disclosed | Sterile fill-finish | medium |
| FaveaFamily-run CDMO for nutraceuticals plus human/veterinary solid dosage (tablets, capsules, pellets). Pharma scope modest vs. supplements. | Kopřivnice, Czechia | Family-owned | Tier 3 | not disclosed | Oral solid dose | medium |
| GalenicaPrivately owned Swedish CDMO (est. 1999); dev + GMP manufacture of solids, liquids, semi-solids, small molecules and peptides incl. high-potency. | Malmö, Sweden | Family-owned | Tier 3 | not disclosed | Oral solid dose, Peptide, Small-molecule API | high |
| GP PharmCDMO focused on highly complex injectables: peptides, oligonucleotides, hormones, liposomes and microspheres. FDA-inspected. | Sant Quintí de Mediona, Spain | Family-ownedParente family | Tier 3 | not disclosed | Peptide, Sterile fill-finish | high |
| HALIXMammalian biologics CDMO: viral vectors, vaccines, recombinant proteins (1,000L SUB). Made AstraZeneca's COVID vaccine. | Leiden, Netherlands | Family-ownedDroege Group | Tier 3 | not disclosed | Viral vector and vaccine, Biologics and biosimilars, Monoclonal antibody | high |
| HAS Healthcare Advanced SynthesisEx-Helsinn HPAPI/anticancer API CDMO spun out as independent in 2022; now parent of Cerbios. | Biasca, Switzerland | Family-ownedBraglia family | Tier 3 | not disclosed | Small-molecule API, Antibody-drug conjugate (ADC) | high |
| Hermes PharmaCDMO specialised in user-friendly oral forms: effervescent, orally-disintegrating granules, lozenges, instant drinks. | Wolfratshausen, Germany | Family-ownedHermes Arzneimittel | Tier 3 | not disclosed | Oral solid dose | medium |
| HiTech HealthFirst Irish company licensed to contract-manufacture cell & gene therapies. End-to-end ATMP CDMO with EU/UK QP release. | Galway, Ireland | Family-owned | Tier 3 | not disclosed | Cell and gene therapy, Viral vector and vaccine, Biologics and biosimilars | high |
| Iasis PharmaProvides CDMO/CMO services alongside own products (since 1985). Broad dosage forms; exports to 36 countries. | Koropi, Greece | Family-owned | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish | high |
| IBI LorenziniAseptic manufacturing of sterile injectables (specialist in sterile penicillins/cephalosporins) plus oral, topical and biotech. | Aprilia, Italy | Family-ownedIbigen Group | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose, Biologics and biosimilars, Monoclonal antibody, Peptide | high |
| IcosagenEnd-to-end mammalian biologics CRDMO: antibody discovery/engineering, CHO cell-line/process dev, and a new GMP facility (50–1000L single-use) for Phase I/II drug substance. | Tartu, Estonia | Family-owned | Tier 3 | not disclosed | Biologics and biosimilars, Monoclonal antibody | high |
| IMUNA PHARMContract manufacturer of sterile infusion and dialysis solutions in single/multi-chamber bags; own brands plus products for multinationals. | Šarišské Michaľany, Slovakia | Family-owned | Tier 3 | not disclosed | Sterile fill-finish | high |
| InnoCore PharmaceuticalsDrug-delivery CDMO for long-acting injectables (microspheres, implants, depot gels) via proprietary SynBiosys polymers. | Groningen, Netherlands | Family-owned | Tier 3 | not disclosed | Peptide, Biologics and biosimilars, Sterile fill-finish | high |
| KeveltEU-GMP Estonian maker of sterile small-volume parenterals, sterile semi-solids and biological medicinal products; seeks contract-manufacturing partnerships. | Tallinn, Estonia | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Biologics and biosimilars | high |
| Klocke Pharma-ServiceContract manufacturing/packaging of solid dosage plus aseptic liquids and lyophilisates. | Appenweier, Germany | Family-ownedKlocke Gruppe | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish | medium |
| Laboratoires SteropSterile injectables/ampoules maker (est. 1947); own essential-medicines portfolio plus CMO services. ~75% export. | Brussels, Belgium | Family-owned | Tier 3 | not disclosed | Sterile fill-finish | high |
| Laboratórios BasiPortuguese pharma (since 1956) offering contract manufacturing for injectables, gels, creams and oral solutions. CMO secondary. | Mortágua, Portugal | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose | medium |
| Lamp San ProsperoItalian oral-solid-dose CDMO. Non-biologics tier-3 addition for completeness. | San Prospero, Italy | Family-owned | Tier 3 | not disclosed | Oral solid dose, Small-molecule API | medium |
| Losan PharmaCDMO for solids, semi-solids, liquids, sachets and effervescent forms; FDA/ANVISA inspected. | Neuenburg am Rhein, Germany | Family-owned | Tier 3 | not disclosed | Oral solid dose | medium |
| LusomedicamentaManufacturer of solid, liquid and semi-solid dosage forms; explicitly lists contract manufacturing. Exports to 47 countries. | Queluz, Portugal | Family-owned | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish | medium |
| MedinfarOperates a CMO/CDMO industrial unit (~20 yrs) alongside its own portfolio; finished dosage forms, galenic, packaging. | Amadora, Portugal | Family-owned | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish | medium |
| Meditop PharmaceuticalFamily-owned Hungarian SME making solid forms with own R&D; lists contract manufacturing but primarily own-product. | Pilisborosjenő, Hungary | Family-owned | Tier 3 | not disclosed | Oral solid dose | low |
| Micro-SphereFounder-led CDMO specialising in spray drying (poorly-soluble drugs) and capsule filling, clinical to commercial. | Monteggio, Switzerland | Family-owned | Tier 3 | not disclosed | Oral solid dose, Small-molecule API | high |
| Miltenyi BioindustryCDMO division of Miltenyi Biotec for lentiviral vectors and cell/gene therapies (supplied LVV for Adaptimmune TECELRA). | Bergisch Gladbach, Germany | Family-ownedMiltenyi Biotec | Tier 3 | not disclosed | Cell and gene therapy, Viral vector and vaccine | low |
| Northway BiotechCEE cost-competitive biologics CDMO scaling to 5,000 L stainless steel. | Vilnius, Lithuania | Family-owned | Tier 3 | n/d | Monoclonal antibody, Microbial and protein, Biologics and biosimilars, Sterile fill-finish, Viral vector and vaccine, Cell and gene therapy | medium |
| Nova LaboratoriesIndependent aseptic-processing CDMO + 'Specials' supplier; sterile fill-finish for clinical-trial medicines. | Leicester, United Kingdom | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Monoclonal antibody, Biologics and biosimilars, Microbial and protein | medium |
| Ovelle PharmaceuticalsFamily-owned (since 1934). Own dermatology brands plus CMO/CDMO manufacturing of cosmetic, medical-device and licensed products. | Dundalk, Ireland | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose | medium |
| Palla Pharma NorwayNorwegian maker of opiate-based APIs and finished dose (est. 1949). Primarily a merchant/own-product opiate-API producer rather than a client-driven CDMO. | Kragerø, Norway | Family-owned | Tier 3 | not disclosed | Small-molecule API, Oral solid dose | low |
| Paras BiopharmaceuticalsFounder-led microbial-biologics CDMO: recombinant biologics/biosimilars in microbial systems, plus peptides and proteins. Scales 10L→750L+. | Oulu, Finland | Family-owned | Tier 3 | not disclosed | Biologics and biosimilars, Microbial and protein, Peptide | medium |
| Pharma ProductionSmall Norwegian CDMO/CMO; contract manufacturing of licensed medicines, IMPs and placebo, plus QC/QP release. Non-sterile fluid/semi-solid forms outside the code set. | Oslo, Norway | Family-owned | Tier 3 | not disclosed | Other dose forms | high |
| PharmpurIndependent family-owned contract manufacturer of sterile liquids in syringes/vials (ophthalmic focus). | Königsbrunn, Germany | Family-owned | Tier 3 | not disclosed | Sterile fill-finish | low |
| Polpharma BiologicsJune 2025 demerger: biosimilars brand stays as Polpharma Biologics (operating from Switzerland); the CDMO becomes Rezon Bio. | Gdańsk, Poland | Family-ownedPolpharma | Tier 3 | ~US$18–100 m est. | Biologics and biosimilars, Monoclonal antibody, Microbial and protein | low |
| Polymun ScientificFamily-owned biopharma/liposome-LNP CDMO; scaled the LNP process for the BioNTech/Pfizer Comirnaty vaccine. | Klosterneuburg, Austria | Family-owned | Tier 3 | not disclosed | Biologics and biosimilars, mRNA and LNP, Viral vector and vaccine | high |
| PrasfarmaCMO/CDMO specialized in cytostatics, HPAPI and oncology; aseptic fill/lyophilization plus solid forms. Annex-1. | Cerdanyola del Vallès, Spain | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose | high |
| Praxis PharmaceuticalCDMO for dev + contract manufacturing of liquid and lyophilised sterile injectables incl. biologics and orphan drugs. Annex-1. | Vitoria-Gasteiz, Spain | Family-owned | Tier 3 | not disclosed | Sterile fill-finish | high |
| ProBioGenIndependent biologics CDMO (proteins/antibodies, viral vectors, vaccines); Charité spin-off, founded 1994. | Berlin, Germany | Family-owned | Tier 3 | not disclosed | Monoclonal antibody, Biologics and biosimilars, Viral vector and vaccine | medium |
| PSMFamily-run aseptic fill-and-finish CDMO; new facility passed EU GMP Annex 1. | Schiffweiler, Germany | Family-ownedTrennheuser family | Tier 3 | not disclosed | Sterile fill-finish | medium |
| Quality ChemicalsIndependent Spanish CDMO (40+ yrs) specializing in inorganic/organic salts in API and excipient grades. GMP/ISO. | Esparreguera, Spain | Family-owned | Tier 3 | not disclosed | Small-molecule API | high |
| Rezon BioCDMO carved out of Polpharma Biologics (June 2025); positions to be Europe's most cost-competitive CDMO. | Gdańsk, Poland | Family-ownedPolpharma | Tier 3 | n/d | Biologics and biosimilars, Monoclonal antibody, Microbial and protein | low |
| Richter BiologicsGerman microbial/biologics CDMO. | Hamburg, Germany | Family-owned | Tier 3 | n/d | Biologics and biosimilars, Microbial and protein | low |
| Richter PharmaFamily pharma group with a GMP contract-manufacturing unit for injectable solutions and semi-solids. | Wels, Austria | Family-owned | Tier 3 | not disclosed | Sterile fill-finish | medium |
| S.A.L.F. Laboratorio FarmacologicoInjectable/infusion sterile solutions (ampoules, bottles, bags) — own portfolio plus explicit contract manufacturing. Since 1921. | Cenate Sotto, Italy | Family-ownedAngeletti family | Tier 3 | not disclosed | Sterile fill-finish | high |
| ScanpharmGMP family-owned combined CMO and contract laboratory (est. 1951); tablets incl. packaging, serialization, testing; small own niche-generics portfolio. | Birkerød, Denmark | Family-owned | Tier 3 | not disclosed | Oral solid dose | high |
| SkyepharmaComplex oral-solid-dose specialist (modified-release, multi-layer/press-coated tablets). Management-owned. | Saint-Quentin-Fallavier, France | Family-ownedOléron Pharma | Tier 3 | ~€20 m+ (site) | Oral solid dose | high |
| Symbiosis Pharmaceutical ServicesIndependent sterile aseptic fill-finish CDMO (clinical + commercial): mAbs, ATMPs, viral vectors, ADCs, vaccines. FDA-inspected. | Stirling, United Kingdom | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Monoclonal antibody, Antibody-drug conjugate (ADC), Biologics and biosimilars, Cell and gene therapy, Small-molecule API | medium |
| SyVento BioTechGreenfield mRNA/LNP CDMO; MIA obtained 31 July 2025. | Skawina, Poland | Family-owned | Tier 3 | early-stage | mRNA and LNP | low |
| ValentisLithuanian group offering contract manufacturing of tablets, capsules, liquids/shots and powders plus primary/secondary packaging. | Kaunas, Lithuania | Family-owned | Tier 3 | not disclosed | Oral solid dose | medium |
| Wasdell GroupUK contract packaging + CDMO (solid/non-sterile dosage, clinical + commercial). Wound down Irish operations in 2024 — verify current status. | Swindon, United Kingdom | Family-owned | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish | medium |
| Wellgem BiopharmaBiologics contract dev/manufacturing: mammalian + microbial cell-line/process dev, cGMP cell banking, Phase II pilot facility. Newer entrant. | Vilnius, Lithuania | Family-owned | Tier 3 | not disclosed | Biologics and biosimilars, Monoclonal antibody, Microbial and protein, Viral vector and vaccine, Cell and gene therapy | medium |
Size: Tier 1 (revenue over €1bn) · Tier 2 (€250m–€1bn) · Tier 3 (under €250m or niche).
Revenue, staff and site figures are as reported and mix audited accounts with commercial estimates, which are often wrong for private companies. Each row carries a confidence mark; verify a figure before quoting it.
Browse the census
Other European CDMO lists
By country
- CDMOs in Italy (31)
- CDMOs in Spain (30)
- CDMOs in Germany (28)
- CDMOs in the United Kingdom (25)
- CDMOs in France (15)
- CDMOs in Switzerland (14)
- CDMOs in Poland (11)
- CDMOs in Belgium (9)
- CDMOs in Sweden (9)
- CDMOs in Greece (8)
- CDMOs in Ireland (8)
- CDMOs in the Netherlands (8)
- CDMOs in Portugal (8)
- CDMOs in Denmark (7)
- CDMOs in Austria (5)
- CDMOs in Finland (5)
- CDMOs in Norway (5)
- CDMOs in Czechia (4)
- CDMOs in Lithuania (4)
- CDMOs in Bulgaria (3)
By modality
- Small-molecule API CDMOs in Europe (107)
- Oral solid dose CDMOs in Europe (94)
- Sterile fill-finish CDMOs in Europe (106)
- Biologics and biosimilars CDMOs in Europe (66)
- Monoclonal antibody CDMOs in Europe (36)
- Antibody-drug conjugate (ADC) CDMOs in Europe (15)
- Cell and gene therapy CDMOs in Europe (29)
- mRNA and LNP CDMOs in Europe (22)
- Viral vector and vaccine CDMOs in Europe (32)
- Microbial and protein CDMOs in Europe (34)
- Peptide CDMOs in Europe (24)
By ownership
- Privately owned CDMOs in Europe (155)
- Family-owned CDMOs in Europe
- Private-equity-owned CDMOs in Europe (54)